|By PR Newswire||
|March 28, 2014 06:41 AM EDT||
LONDON, March 28, 2014 /PRNewswire/ --
On Wednesday, March 26, 2014, the NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones Industrial Average fell 0.60% to 16,268.99, and the S&P 500 closed at 1,852.56, down 0.70%. The losses were broad based as nine out of 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 672.05, up 0.05%, and the same has gained 4.63% in the last three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and ISIS can be downloaded upon signing up at:
Array BioPharma Inc.'s stock lost 3.43% on Wednesday, closing at $4.79, after oscillating between $4.75 and $5.01. A total of 1.63 million shares were traded, which is above its three months average volume of 1.35 million. Array BioPharma Inc.'s shares have fallen by 5.15% in the last one month and 4.39% on YTD basis, while the same has gained 1.70% in the previous three months. The company's stock is trading below its 50-day and 200-day moving averages. Array BioPharma Inc.'s 200-day moving average of $5.44 is above its 50-day moving average of $5.05. Furthermore, the stock is trading at a Relative Strength Index (RSI) of 45.70. Sign up today to read free research on ARRY at:
Shares in ACADIA Pharmaceuticals Inc. witnessed a trading volume of 2.26 million shares on Wednesday, as compared with a three months average volume of 1.85 million shares. The stock ended the day at $22.90, down 3.82% and at an intraday trading range of $22.80 and $24.33 during the session. Shares in ACADIA Pharmaceuticals Inc. have declined 22.95% in the last one month and 8.36% on YTD basis. The stock is trading above its 200-day moving average. ACADIA Pharmaceuticals Inc.'s 50-day moving average of $25.59 is above its 200-day moving average of $22.86. Additionally, the company's shares are trading at an RSI of 38.16. Sign up today to read free research on ACAD at:
On Wednesday, Pharmacyclics Inc.'s stock declined 1.60% finishing the session at $108.95. The stock recorded a trading volume of 1.62 million shares which is above its three months average volume of $1.22 million. The stock fluctuated between $108.77 and $113.50 during the session. Pharmacyclics Inc.'s shares have lost 25.47% in the last one month, while the same has gained 0.82% in the previous three months and 3.00% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Pharmacyclics Inc.'s 50-day moving average of $133.57 is above its 200-day moving average of $118.23. Moreover, the shares are trading at a PE ratio of 136.19 and at an RSI of 25.78. Sign up today to read free research on PCYC at:
Shares in Isis Pharmaceuticals Inc. recorded a trading volume of 1.75 million shares, as compared with a three months average volume of 1.71 million shares. The stock ended Wednesday's session at $42.07, down 3.38%, and at an intraday trading range of $41.82 and $45.05. Shares in Isis Pharmaceuticals Inc. have surged 2.68% in the previous three months and 5.60% on YTD basis. The stock is trading above its 200-day moving average. Isis Pharmaceuticals Inc.'s 50-day moving average of $49.95 is above its 200-day moving average of $36.73. Further, the company's shares are trading at an RSI of 36.83. Sign up today to read free research on ISIS at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.